Search by BoMiProt ID - Bomi3249


Primary Information

BoMiProt ID Bomi3249
Protein Name lumican isoform X1
Organism Bos taurus
Uniprot IDQ05443
Milk FractionWhey
Ref Sequence ID NP_776359.1
Aminoacid Length 342
Molecular Weight 38756
FASTA Sequence Download
Gene Name LUM
Gene ID 280847
Protein Existence Status Reviewed: Experimental evidence at protein level

Secondary Information

Protein Function lumican acts as a cancer prognosis marker, chemoresistance regulator, and cancer therapy target.
Biochemical Properties Lumican, a class II SLRP, has a 38 kDa protein core exhibiting four distinct regions: a 16 amino acid peptide, a negatively charged N-terminal region containing tyrosine sulfate and disulfide bonds, a 6–10 LRR motifs characterized by common molecular architecture that supports protein interactions, and a C-terminal region consisting of two conserved cysteine residues.
PTMs Disulfide bond formation,N-Linked Glycosylation at Asn, Phosphorylation at Ser, Sulfation at Tyr
Site(s) of PTM(s)

N-glycosylation, O-glycosylation,
Phosphorylation
Predicted Disorder Regions NA
DisProt Annotation
TM Helix Prediction No TM helices
Significance of PTMs Most SLRP family members undergo different post-translational glycosylation and are competent to regulate signal transduction mechanisms, and affect various cellular functions, like proliferation, migration, and differentiation.
Bibliography 1.Giatagana EM, Berdiaki A, Tsatsakis A, Tzanakakis GN, Nikitovic D. Lumican in Carcinogenesis-Revisited. Biomolecules. 2021 Sep 6;11(9):1319. doi: 10.3390/biom11091319. PMID: 34572532; PMCID: PMC8466546. 2.Onnerfjord P, Heathfield TF, Heinegård D. Identification of tyrosine sulfation in extracellular leucine-rich repeat proteins using mass spectrometry. J Biol Chem. 2004 Jan 2;279(1):26-33. doi:10.1074/jbc.M308689200. Epub 2003 Oct 8. PMID: 14551184. 3.Small leucine rich proteoglycans, a novel link to osteoclastogenesis.Kram V, Kilts TM, Bhattacharyya N, Li L, Young MF Sci Rep. 2017 Oct 3;7(1):12627. 4.Proteoglycans in the Pathogenesis of Hormone-Dependent Cancers: Mediators and Effectors.Tzanakakis G, Giatagana EM, Kuskov A, Berdiaki A, Tsatsakis AM, Neagu M, Nikitovic D Cancers (Basel).2020 Aug 24; 12(9):. 5. The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis.Tzanakakis GN, Giatagana EM, Berdiaki A, Spyridaki I, Hida K, Neagu M, Tsatsakis AM, Nikitovic D Cancers (Basel). 2021 May 19; 13(10):.